ALSO NOTED: YM cuts losses;French launch vaccines probe; diabetes foundation contributes research funds; and much more...

> YM Biosciences managed to halve its pre-tax loss for the first half by cutting expenses. Release

> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report

> The Juvenile Diabetes Research Foundation is giving Plureon $500,000 over two year to research new treatments for type 1 diabetes. Report

> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report

> When the American College of Cardiology sent out its annual meeting agenda, the controversial ENHANCE study wasn't listed as a highlighted presentation. Report

> Manhattan Pharmaceuticals has entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin, the company's novel, non-insecticide treatment for head lice. Release

> Twenty-three people have died after being injected with colchicine, a gout drug that's FDA-approved only for oral use. Report

> A few hours of extreme drowsiness is not a bad trade-off for schizophrenia patients who have problems sticking to their medication. So said an FDA advisory committee yesterday in backing approval of Eli Lilly's new long-acting, injectable form of Zyprexa. Report

> Plummeting Avandia sales have taken a toll on GlaxoSmithKline's bottom line. Report

And Finally… Researchers can now use a transparent zebrafish to help them advance their understanding of disease. Release

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.